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Linking minimum inhibitory 
concentrations to whole genome 
sequence-predicted drug resistance 
in Mycobacterium tuberculosis 
strains from Romania
Carolien Ruesen  1, Anca Lelia Riza1,2, Adriana Florescu3, Lidya Chaidir4, Cornelia Editoiu3, 
Nicole Aalders5, Dragos Nicolosu3, Victor Grecu3, Mihai Ioana2, Reinout van Crevel1 &  
Jakko van Ingen  5
Mycobacterium tuberculosis drug resistance poses a major threat to tuberculosis control. Current 
phenotypic tests for drug susceptibility are time-consuming, technically complex, and expensive. 
Whole genome sequencing is a promising alternative, though the impact of different drug resistance 
mutations on the minimum inhibitory concentration (MIC) remains to be investigated. We examined the 
genomes of 72 phenotypically drug-resistant Mycobacterium tuberculosis isolates from 72 Romanian 
patients for drug resistance mutations. MICs for first- and second-line drugs were determined using 
the MycoTB microdilution method. These MICs were compared to macrodilution critical concentration 
testing by the Mycobacterium Growth Indicator Tube (MGIT) platform and correlated to drug resistance 
mutations. Sixty-three (87.5%) isolates harboured drug resistance mutations; 48 (66.7%) were 
genotypically multidrug-resistant. Different drug resistance mutations were associated with different 
MIC ranges; katG S315T for isoniazid, and rpoB S450L for rifampicin were associated with high MICs. 
However, several mutations such as in rpoB, rrs and rpsL, or embB were associated with MIC ranges 
including the critical concentration for rifampicin, aminoglycosides or ethambutol, respectively. 
Different resistance mutations lead to distinct MICs, some of which may still be overcome by increased 
dosing. Whole genome sequencing can aid in the timely diagnosis of Mycobacterium tuberculosis drug 
resistance and guide clinical decision-making.
Drug-resistance poses a major threat to tuberculosis (TB) control. Global surveillance data suggest that in 2015, 
there were an estimated 480.000 new cases of multidrug-resistant TB (MDR-TB), i.e. resistant to at least isoniazid 
(INH) and rifampicin (RIF), and that 9.5% of these cases were extensively drug-resistant (XDR), i.e. also resistant 
to amikacin (AMI), kanamycin (KAN), or capreomycin (CAP), and at least one fluoroquinolone (FLQ)1. It is 
estimated that less than half of these cases are detected, and an even smaller proportion receive appropriate treat-
ment1. One of the main problems in the control of drug-resistant TB (DR-TB) is the lack of laboratory capacity to 
diagnose resistance2. Conventional culture-based drug susceptibility testing (DST) is expensive, time-consuming 
and requires a specialized biosafety laboratory. Methods for DST for many of the second-line drugs have not yet 
been fully standardized3. In addition, these phenotypic methods often rely on growth of mycobacterial cultures 
in the presence of a single ‘critical’ drug concentration to distinguish resistant and susceptible strains based on 
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epidemiological breakpoints, which are near the wild type minimum inhibitory concentration (MIC) distribution 
for some drugs4.
Molecular assays are now available and can overcome some of the disadvantages of phenotypic methods to 
diagnose DR-TB. Yet, these assays are expensive and cannot identify all of the genetic loci associated with drug 
resistance5,6. Whole genome sequencing (WGS) of M. tuberculosis, tackles this problem and could enable the 
reliable prediction of the drug susceptibility phenotype within a clinically relevant timeframe. A fundamental 
issue in the application of WGS to predict drug resistance is how to interpret mutations in relation to phenotypic 
antibiotic resistance. The level of resistance, reflected by the MIC, a single nucleotide polymorphism (SNP) causes 
is most important for clinicians treating patients, in order to determine whether to increase the dosage or change 
the regimen.
Therefore, in the current study we provide this missing link by comparing MICs to drug resistance mutations 
determined by WGS. For this purpose we used a collection of drug-resistant strains from Romania, which had 
20,000 new TB cases, and 800 new MDR-TB cases in 2012, making it one of the 18 high-priority countries for TB 
control in the World Health Organization (WHO) European Region7.
Methods
Selection of M. tuberculosis isolates. We used M. tuberculosis isolates from the bio-archive established at 
the TB laboratory of the Clinical Hospital of Infectious Diseases and Pneumophtisiology “Victor Babes” Craiova 
between 2014 and 2016. The laboratory runs approximately 7,000 sputum samples per year, covering much of 
the TB epidemic in Dolj county. Routine diagnostics as indicated by the National Control Programme include 
sputum microscopy and culture on Löwenstein-Jensen medium (liquid media introduced in May 2015). After 
primary culture on Löwenstein-Jensen medium, screening for INH and RIF-resistance is performed using INH 
0.2 mg/l and RIF 40 mg/l-supplemented Löwenstein-Jensen slants.
All 73 isolates that were phenotypically resistant to INH and/or RIF were selected for the purpose of the 
present study. All 73 isolates were from different patients, and no serial isolates were included. Isolates stored in 
trypticase soy broth supplemented with glycerol were sub-cultured on Löwenstein-Jensen medium. Sub-cultured 
colonies were used for DNA extraction, and susceptibility testing.
Phenotypic drug susceptibility testing. All isolates were simultaneously subjected to MIC determi-
nations of rifampicin, rifabutin, ethambutol, streptomycin, amikacin, kanamycin, ofloxacin, moxifloxacin, 
para-aminosalicylic acid (PAS), ethionamide and cycloserine by broth microdilution in Middlebrook 7H9 
broth (SensiTitre MycoTB assay; Trek Diagnostics/ThermoFisher, Landsmeer, the Netherlands). Every isolate 
was tested once, unless contamination or no growth was observed; then the isolate was re-cultured and once 
more subjected to MIC testing. The MycoTB assay is a new method for susceptibility testing of M. tuberculosis 
complex8,9. The plate uses a 96-well microtiter broth format and contains 12 lyophilized first- and second-line 
anti-mycobacterial drugs. In contrast to other M. tuberculosis complex susceptibility methods, which test one 
or two critical concentrations of a drug, the MycoTB assay examines a range of drug concentrations and pro-
duces an MIC result. In addition, critical concentration testing for streptomycin, isoniazid, rifampicin and eth-
ambutol (SIRE assay; BD BioScience, Erembodegem, Belgium) was performed using the Mycobacterium Growth 
Indicator Tube (MGIT) macrodilution platform (BD BioScience, Erembodegem, Belgium). The critical concen-
trations used for MGIT testing were 0.10 µg/ml for INH, 1.00 µg/ml for RIF, 5.00 µg/ml for EMB, and 1.00 µg/ml 
for STR. Technicians performing susceptibility tests were blinded to the sequencing results.
Whole genome sequencing and in silico determination of drug resistance. DNA isolation using 
UltraClean® Microbial DNA Isolation Kit (MO BIO Laboratories Inc., Carlsbad, CA) was followed by quanti-
tative (Qubit v3.0) and qualitative assessment of the DNA (gel electrophoresis). We used the Nextera XT DNA 
Library Preparation Kit (Illumina, San Diego, CA) for library preparation. M. tuberculosis DNA was sequenced 
on an Illumina NextSeq500 instrument using 2 × 150 bp paired-end reads. One isolate was excluded due to failed 
library preparation, resulting in a total set of 72 isolates. No internal control was performed for WGS. After 
sequencing, the raw FASTQ sequence reads were filtered using Trim Galore (http://www.bioinformatics.babra-
ham.ac.uk/projects/trim_galore), including removing of adapter sequences. Sequencing coverage was deter-
mined using the FASTQC quality control tool version 0.10.1, and the Genome Analysis Toolkit10. The average 
proportion of bases sequenced with a sequencing error rate of 0.1% or less per base was 77.8% per genome. The 
average coverage depth for the 72 sequenced strains was 165.1, and the average percentage of bases covered by at 
least one read was 99.5%. Quality control statistics are shown in supplementary Table 1.
Raw FASTQ sequencing files were uploaded to TB Profiler version 0.2.1, an online tool to determine drug 
resistance in silico11. It uses raw sequence data as input, aligns these to the M. tuberculosis H37Rv reference 
genome, and compares identified single nucleotide polymorphisms (SNPs) and indels to a curated list of 1,325 
drug resistance mutations. Although it allows examining heteroresistance, we focused on majority variants. In 
addition, it determines the M. tuberculosis lineage based on a 62-SNP barcode12. The TB Profiler-predicted resist-
ance mutations were validated using PhyResSE, version 1.013, another online tool that maps raw sequencing reads 
to the M. tuberculosis H37Rv reference strain to report drug resistance and phylogenetic SNPs. We used the M. 
tuberculosis complex numbering system, based on the sequence of the reference strain; H37Rv14.
Phylogeny construction. A phylogeny was constructed to examine clustering of the isolates. The sequence 
reads were aligned to reference strain M. tuberculosis H37Rv, accession number NC_000962.3, and variants were 
called using Breseq software, version 0.27.115. We extracted all 5,980 variable positions across the 72 M. tuberculo-
sis sequences and concatenated them into a single alignment. Solely for the purpose of creating the phylogenetic 
tree, SNPs occurring in PE/PPE genes, genes related to mobile elements, as well as genes previously associated 
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with drug resistance11 were removed. The remaining 5,794 SNPs were used to construct the phylogenetic tree 
using PhyML, version 3.016 using the HKY85 model with four categories for the gamma distribution, and using 
a hundred bootstraps.
Comparison of MGIT, minimum inhibitory concentrations and whole genome sequencing. For 
each isolate, susceptibility to STR, INH, RIF, and EMB as determined by MGIT was compared to the MICs 
determined by MycoTB. If MycoTB MICs were higher than the critical concentration (>0.25 µg/ml for INH, 
>1.0 µg/ml for RIF, >4.0 µg/ml for EMB, and >2.0 µg/ml for STR17, the isolate was considered resistant to the 
respective drug. Cohen’s kappa statistic was calculated for each drug to determine the level of agreement between 
MycoTB- and MGIT-determined resistance. In addition, drug resistance mutations identified by TB Profiler and/
or PhyResSE were correlated to MGIT results and MICs. We visualized the MIC for each drug in histograms, 
and subsequently determined the frequencies of the individual resistance-determining mutations and plotted 
their distributions against the MGIT results for INH, RIF, EMB, and STR, and against the MICs for first- and 
second-line drugs. For isolates with discrepant susceptibility results for INH or RIF between WGS and MGIT, 
we compared the MGIT to the DST performed on Löwenstein-Jensen and in case of genotypically resistant, phe-
notypically susceptible isolates we examined the quality of the variant call (Supplementary Table 2). All analyses 
were performed in R, version 3.3.1 (http://www.R-project.org).
Data availability. The raw sequence files (FASTQ) were archived on the NCBI Sequence Read Archive and 
are available at: (URL will be included after sequence file shave been uploaded). The individual isolates can be 
accessed under the following Biosample accession numbers: SAMN09402650-SAMN09402721. The Bioproject 
accession number is: PRJNA475771.
Results
Phenotypic drug susceptibility testing. MGIT results for INH, STR, and EMB were available for 68 
out of 72 isolates (four cultures being contaminated); RIF MGIT results were available for 69 isolates, with three 
cultures contaminated. Fifty-seven isolates were phenotypically resistant to INH, 34 to RIF, 24 to STR, and three 
to EMB. Using the MycoTB microdilution method, MICs for INH, RIF, STR, EMB, ETO, OFL, MXF, PAS, cyclos-
erine, AMK, and KAN were successfully determined for 64 isolates; six samples were contaminated, and two 
repeatedly failed to grow in the MycoTB plate. By MycoTB, 51 isolates were resistant to INH, 31 to RIF, nine to 
STR, four to EMB, 40 to ETO, four to OFL, one to MXF, one to PAS, one to cycloserine, two to AMK, and three 
were resistant to KAN (Supplementary Figure 1). Poly-drug resistance was observed in 47, and MDR-TB in 28 
isolates, no isolates were XDR-TB according to MycoTB. The agreement between MGIT and MycoTB for INH, 
RIF, STR and EMB was greater than to be expected by chance (Supplementary Table 3). Cohen’s kappa indicated 
excellent agreement for INH (κ = 0.794; p < 0.001) and RIF (κ = 0.905; p < 0.001), and little agreement for STR 
(κ = 0.289; p = 0.006) and EMB (κ = 0.246; p = 0.045).
Whole genome sequencing and in silico determination of drug resistance. Sixty-three (87.5%) 
isolates harboured drug resistance-conferring mutations, and 48 (66.7%) had INH and RIF resistance-conferring 
mutations and were genotypically multidrug-resistant. The identified drug resistance mutations are listed 
in Table 1. Resistance-conferring mutations to INH were identified in 61 (84.7%) isolates. The most com-
mon INH resistance mutation was katG S315T, which was present in 38 (52.8%) isolates as a single muta-
tion, and in 16 (22.2%) together with a mutation in the fabG1 promotor region (synonym: inhA promotor 
region). Resistance-conferring mutations to RIF were found in 50 (69.4%) isolates. The most prevalent RIF 
resistance-conferring mutation was rpoB S450L, observed in 17 (23.6%) isolates as a single mutation, and in one 
isolate as a combined mutation. Mutations in genes related to EMB susceptibility were identified in 39 (54.2%) 
isolates; embB M306I was observed in 25 (34.7%) isolates, and in 14 of these as a single mutation. Resistance to 
STR due to mutations in the rpsL and rrs loci was found in 19 (26.4%) isolates; with rrs A1401G in 13 isolates 
being the most frequent. This mutation however is not considered causative of STR resistance according to expert 
knowledge18,19. Mutations in the pncA gene, encoding the target of PZA were found in 23 (31.9%) isolates, 14 of 
which had a single pncA A146V mutation. Mutations to second-line drugs were less frequently observed, the rrs 
A1401G mutation associated with resistance to AMK, CAP, and KAN was most common, together with the C15T 
mutation in the promotor region of fabG1 conferring resistance to ETO that was found in 20 (27.8%) isolates. 
The latter mutation is also associated with INH resistance. Only five isolates had one of four different mutations 
conferring resistance to FLQs.
Phylogenetic relatedness of the isolates. A phylogenetic tree was constructed based on 5,794 vari-
able common nucleotide positions among the 72 M. tuberculosis isolates. Seventy-one isolates belonged to the 
Euro-American lineage and one belonged to the East-Asian lineage. The phylogeny showed that several isolates 
were closely related, but did not all harbour the same resistance-conferring mutations (Supplementary Figure 2). 
Fourteen isolates within the same clade carried the fabG1 (C-15T promotor), katG (S315T), rpoB (S450L), embB 
(M306I), and pncA (A146V) mutations, but they also harboured different mutations. Another 21 isolates clus-
tered together in the tree and carried the S315T katG mutation, twenty of them had the H445N rpoB mutation, 
but apart from that their resistance profile differed. In addition, there were five pairs of neighbouring isolates that 
had similar resistance mutations.
Comparison of MGIT, minimum inhibitory concentrations and whole genome sequencing. 
First, whole genome sequencing was compared with phenotypic DST by MGIT. Supplementary Figure 3 and 
Table 1 show the comparison of MGIT and WGS resistance prediction. For MGIT, all isolates with well-known 
INH resistance-conferring mutations were phenotypically resistant to INH, and all isolates without these 
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Drug Gene Mutation Frequency (%)
MGIT-
resistant# MIC > CC#
INH
katG Ser315Thr 38 (52.8) 35/35 30/30
katG + ahpC Asp311Gly + G-48A promoter 1 (1.4) 1/1 1/1
katG + fabG1 Ser315 Thr + C-15T promoter 16 (22.2) 15/15 16/16
fabG1 C-15T promoter 4 (5.6) 4/4 2/4
fabG1 + inhA C-15T promoter + Ile21Val 1 (1.4) 1/1 0/1
ahpC C-52T promoter 1 (1.4) 1/1 1/1
RIF
rpoB Asp435Val 4 (5.6) 3/4 3/4
Gln432Pro 1 (1.4) 1/1 1/1
His445Asn 12 (16.7) 2/11 1/7
His445Asp 1 (1.4) 1/1 1/1
His445Tyr 4 (5.6) 4/4 4/4
Leu430Pro 2 (2.8) 0/1 0/1
Ser450Leu 17 (23.6) 15/15 16/16
Ser450Trp 1 (1.4) 1/1 1/1
Asp435Gly + His445Asn 1 (1.4) 1/1 1/1
Asp435Val + His445Asn 1 (1.4) 1/1 NA
His445Asn + Pro454Leu 2 (2.8) 0/2 1/2
Leu430Pro + His445Asn 1 (1.4) 1/1 NA
Met434Ile + His445Asn 1 (1.4) 1/1 1/1
Phe424Leu + His445Asn 1 (1.4) 1/1 0/1
His445Asn + Ser450Leu + Pro454Leu 1 (1.4) 1/1 0/1
EMB
embA C-12T promoter 1 (1.4) 0/1 0/1
embA + embB C-12T promoter + Asp354Ala 1 (1.4) 0/1 0/1
C-12T promoter + Glu504Asp 1 (1.4) 0/1 0/1
C-12T promoter + Met306Ile 1 (1.4) 0/1 0/1
C-12T promoter + Met306Leu + Asp354Ala 1 (1.4) 0/1 0/1
embB Asp354Ala 1 (1.4) 0/1 0/1
Gly406Asp 5 (6.9) 0/5 0/1
Met306Ile 14 (19.4) 0/12 0/14
Met306Leu 1 (1.4) 0/1 0/1
Met306Val 2 (2.8) 0/2 0/1
Met306Ile + Gly406Asp 9 (12.5) 3/9 4/8
Met306Val + Asp328Tyr 1 (1.4) 0/1 0/1
Met306Ile + Tyr319Ser + Asp354Ala 1 (1.4) 0/1 0/1
STR
rpsL Lys43Arg 1 (1.4) 1/1 1/1
Lys88Arg 1 (1.4) 1/1 1/1
rpsL + rrs Lys43Arg + A1401G 2 (2.8) 2/2 2/2
rrs A1401G* 11 (15.3) 6/10 1/10
A514C 2 (2.8) 2/2 2/2
C1402T* 1 (1.4) 1/1 0/1
C517T 1 (1.4) NA 0/1
PZA
pncA Ala146Val 14 (19.4) NA NA
Gln10Arg 1 (1.4) NA NA
Gln10Stop 4 (5.6) NA NA
Gly17Asp 2 (2.8) NA NA
Tyr34Stop 1 (1.4) NA NA
Tyr34Stop + Gly17Asp 1 (1.4) NA NA
ETO
ethA Thr61Met 1 (1.4) NA 1/1
fabG1 C-15T promoter 20 (27.8) NA 19/19
fabG1 + inhA C-15T promoter + Ile21Val 1 (1.4) NA 1/1
FQ
gyrA Ala90Val 1 (1.4) NA NA
Asp94Gly 2 (2.8) NA 1/2 (OFL); 0/2 (MXF)
Ser91Pro 1 (1.4) NA 0/1 (OFL); 0/1 (MXF)
gyrB Asp461Asn 1 (1.4) NA 1/1 (OFL); 0/1 (MXF)
Continued
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mutations were susceptible to INH. For RIF, 13/69 (19%) discrepancies were observed between MGIT and 
WGS; all concerned WGS-resistant, MGIT-susceptible isolates. Eleven of these had a H445N rpoB mutation; 
eleven were susceptible according to DST performed on Löwenstein-Jensen medium, and variant call qualities 
were good (Supplementary Table 2). For STR, WGS and MGIT did not match for 15/68 (22%) isolates; four 
had an A1401G rrs mutation but were susceptible according to MGIT, and 11 were MGIT-resistant, but had no 
STR resistance-conferring mutations. For EMB, we observed 34/69 (49%) discrepancies; all isolates without an 
EMB resistance-conferring mutation were susceptible, but 34 isolates with an EMB resistance mutation were 
also susceptible. Only isolates with the combination of two embB mutations (M306I and G406D) were MGIT 
EMB-resistant, and this was only the case for 3 out of 9 isolates with this combined mutation.
We next compared WGS with the MycoTB assay, which yields MICs (Fig. 1 and Table 1). Different resistance 
mutations were associated with different MIC ranges. For INH, the katG S315T mutation was associated with 
clearly elevated MICs, as was the ahpC C52T promotor mutation although it only occurred in one isolate. Other 
mutations in ahpC, fabG1, and inhA were associated with MICs around or just above the critical concentration. 
For RIF, the rpoB S450L mutation was associated with elevated MICs, but other rpoB mutations were associated 
with a range of MICs including the critical concentration. Mutations in rpsL were all associated with MICs above 
the critical concentration for STR and the same applies to the rrs A514C mutation. However, other rrs mutations 
were associated with MICs around or below the critical concentration for STR. All found mutations in embA 
or embB were associated with elevated EMB MICs; their ranges included the critical concentration. All isolates 
with resistance-conferring mutations to ETO had elevated MICs. The fabG1 C15T promotor mutation was asso-
ciated with a bimodal MIC distribution for ETO; some isolates had an MIC of twice the critical concentration; 
most others with the mutation had an eight times higher MIC than the critical concentration. For AMK and 
KAN, all observed mutations were associated with an MIC range below or including the critical concentration. 
OFL or MXF resistance mutations were uncommon, and these mutations were associated with an MIC above 
the critical concentration in only two isolates, and only for OFL. For STR and OFL, but especially for ETO, we 
observed isolates with no mutations conferring resistance to the respective drug, but with MICs above the critical 
concentration.
Discussion
In this study, we demonstrate that MIC determination using SensiTitre MycoTB is an excellent alternative to con-
ventional DST methods; it is relatively rapid, straightforward, and it provides quantitative data on susceptibility 
to first- and second-line drugs, thus facilitating therapeutic decision-making and therapeutic drug monitoring 
to optimize regimen efficacy and minimize toxicity20. Whole genome sequencing has been shown to be a sen-
sitive, accurate, rapid, and financially feasible method for M. tuberculosis drug susceptibility testing21. Here we 
show that WGS has additional added value in terms of predicting the level of resistance to different drugs. For 
key anti-tuberculosis drugs including rifampicin, isoniazid, ethambutol and fluoroquinolones, distinct genomic 
mutations are associated with particular MIC ranges, some including the critical concentration.
The MycoTB microdilution method is a commercially available method for MIC testing in M. tuberculosis 
and the first for second-line drugs. Previous studies have tested its performance compared to currently avail-
able methods for drug susceptibility testing, such as the BACTEC MGIT 96022, the indirect agar proportion 
method8,9,23, the Löwenstein-Jensen proportion method24, genotypic tests25, or a combination of these17, and it 
has proven a rapid, convenient, quantitative, and accurate method for testing both first- and second-line antitu-
berculosis drug susceptibility. Although we found discrepancies with WHO-endorsed phenotypic tests for first 
line drugs, especially STR and EMB, phenotypic DST has been proven to be difficult for these drugs and the value 
of these tests as ‘gold standard’ is questionable. Compared to previous studies comparing MycoTB with MGIT, 
the MycoTB in the present study performed slightly better for INH and RIF, comparable for EMB, and slightly 
worse for STR17,22. Furthermore, the microwell plate format without the need for equipment will allow its use in 
resource-pour settings, where it is most needed, provided that culture-based DST is possible, and proper biosafety 
measures are taken. Moreover, the visual reading of the plates requires some operator experience.
Whole genome sequencing is revolutionizing drug susceptibility testing in tuberculosis and has great poten-
tial in public health interventions. However, the various platforms used, as well as the shortcomings of critical 
Drug Gene Mutation Frequency (%)
MGIT-
resistant# MIC > CC#
AMK
rrs A1401G 13 (18.1) NA 2/12
A514C* 2 (2.8) NA 0/2
C1402T 1 (1.4) NA 0/1
C517T* 1 (1.4) NA 0/1
CAP
rrs A1401G 13 (18.1) NA NA
C1402T 1 (1.4) NA NA
KAN
eis G-14A promoter 2 (2.8) NA 1/2
rrs A1401G 13 (18.1) NA 1/12
C1402T 1 (1.4) NA 0/1
Table 1. Frequency of M. tuberculosis resistance-conferring mutations. *These mutations possibly have no 
causative role in conferring drug resistance to the respective drug18,19. #Presented as N/N tested, because not all 
isolates with genotypic DST results had phenotypic DST results. The most frequently found mutations per drug 
are shown in bold.
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concentrations for phenotypic DST hinder the comparison of genotypic and phenotypic DST, hence the valida-
tion of WGS-based susceptibility testing26. The current critical concentrations have a limited evidence base and 
stem largely from observations on wild type MIC distributions, not from clinical or pharmacokinetics/pharma-
codynamics studies27. Data from several studies indicate that these critical concentrations need to be revised 
because they either bisect the wild-type distribution, or are substantially higher than the MICs of wild-type 
organisms resulting in potential false reporting of susceptibility28. Indeed, in the current study, we observed that 
isolates with mutations associated with decreased susceptibility to RIF, STR, and EMB were reported susceptible 
according to MGIT, and MICs for these drugs were often around the critical concentration. These data support 
the notion of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) that critical concen-
trations should be defined by combining MIC distributions, preferably combined with clinical outcomes and 
pharmacokinetics/pharmacodynamics data28,29. Even though WGS has already been successfully implemented 
in routine diagnostic practice in some settings and has been shown to achieve generally high agreement with 
phenotypic first-line DST21,30,31, MIC testing may help in more accurately assessing the performance of WGS for 
drug resistance detection and the role of this method in TB laboratory diagnosis.
The discrepancies between MGIT and MICs observed in our study support the current dogma that incon-
sistencies between phenotypic and genotypic DST found in important studies investigating the use of WGS for 
predicting Mycobacterium tuberculosis drug susceptibility are partly attributed to shortcomings with currently 
endorsed methods of phenotypic DST, which essentially provide only qualitative results (sensitive or resist-
ant), especially where mutations conferring low-level drug resistance are involved32. However, it is important 
to appreciate that unknown resistance mechanisms, inadequate limits of detection or artefacts of sequencing, 
random errors, and false associations between genotype and phenotype due to epistatic interactions could all play 
a role33–35. The clinical impact of these discrepancies, and the effect of treatment regimen based on different DST 
methods are not clear yet, and clinical validation of the influence of MICs of single drugs on treatment outcome is 
warranted. The analysis of embB mutations has long been considered futile because they did not match well with 
phenotypic DST results36, our data however show that these mutations do have an effect on MICs thus potentially 
influence treatment efficacy37,38 as has been shown previously in a mouse model of aerogenic tuberculosis39.
Similar to what has been shown in a recent study by Heyckendorf et al.32, we observed that WGS did not 
miss phenotypically confirmed resistances to first-line drugs, except for STR. We discovered that the MIC-range 
for isolates without STR resistance-conferring mutations was wide and included the critical concentration. 
Unknown mutations in these isolates could have caused resistance. Critical concentration artefacts could also 
explain the discrepancies; 16 isolates were MGIT-resistant for STR, but had an MIC below the critical concentra-
tion. In addition, WGS predicted resistance in a number of phenotypically susceptible isolates. Especially rpoB 
H445N, embB G406D and M306I, as well as the rrs mutations did not correlate well with phenotypic resistance, 
in line with previous findings19,26,40–42. We found that these mutations increased the MIC only slightly, or were 
Figure 1. Drug resistance mutations with corresponding minimum inhibitory concentrations for nine anti-
tuberculous drugs. Each dot represents an isolate and is coloured by mutation. AhpC C-52T, G-48A, fabG1 
C-15T, and eis G-14A are mutations in the promotor area of the respective gene. The y-axes show the minimum 
inhibitory concentrations in μg/ml. NOTE. Dots may be shown in-between tested MICs to increase readability.
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associated with wide MIC-ranges. However, previous studies have shown that these mutations may still be clini-
cally relevant37,39,41,43,44.
This is the first study to investigate drug resistance in M. tuberculosis isolates from the greater Craiova area, 
Romania. In this selection of phenotypically drug-resistant isolates we observed low frequencies of resistance to 
second-line drugs, possibly as a result of limited availability of second-line anti-TB drugs7. Surprising was the 
observation that all-but-one of the isolates belonged to the Euro-American lineage, because there has been an 
extremely large cluster of MDR/XDR-TB Mycobacterium tuberculosis strains in the EU, especially in the eastern 
part, which is significantly related to the spread of one strain or clone of the Beijing genotype45.
The relatively small number of isolates does not permit drawing solid conclusions on the effect of most drug 
resistance mutations on drug susceptibility and the interrelatedness of different mutations, or their combined 
effects on the level of resistance. However, the findings we present are an important contribution to the field 
because of a lack of data correlating M. tuberculosis genotype and MICs46. In addition, the phylogeny showed 
one clade of genetically closely related isolates. This could have affected the MIC distribution of the drugs these 
isolates are resistant to. However, the drug resistance mutations found in these isolates differed to an extent that 
makes it unlikely that these isolates represent the same strain. Also, we could not associate drug resistance muta-
tions with the corresponding MICs for two strains that failed to grow on the MycoTB microtiter plate and six that 
were contaminated. Lastly, pyrazinamide is not included in the MycoTB plate, and we could not assess the MICs 
related to pyrazinamide resistance-associated mutations, which were discovered in 23 (32%) isolates.
In summary, we have shown that, especially for RIF, STR, and EMB, MICs near the critical concentration are 
common. Consequently, phenotypic DST based on critical concentration testing, e.g. the MGIT method, may 
provide inaccurate results, possibly leading to suboptimal treatment regimens. We compared WGS-predicted 
drug resistance mutations directly with MICs and found that different mutations lead to different levels of resist-
ance; knowing the underlying mutations can guide clinical decision-making and facilitate therapeutic drug mon-
itoring, ultimately leading to better treatment outcome.
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